Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023
Upcoming healthcare industry conferences include:
2023 Cell & Gene Meeting on the Med
Tom Wilton , Chief Business Officer, will give a corporate presentation.Thursday, April 13, 2023 at10:45 am CET Barcelona, Spain
Carisma will present three data abstracts during the meeting:- Macrophages engineered with cytokine switch receptors: Development of a modular platform for rebalancing inflammation in microenvironments;
- A mesothelin targeting chimeric antigen receptor macrophage (CAR-M) for solid tumor immunotherapy: pre-clinical development of CT-1119; and
- A Phase 1, First-in-Human study of autologous anti-HER2 CAR-M in participants with HER2 overexpressing solid tumors.
Friday, April 14 toWednesday, April 19, 2023 Orlando, Florida
Upcoming investor conferences include:
Needham 22nd Annual
Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat and will give a corporate presentation.Thursday, April 20, 2023 at12:45 pm EDT - Virtual
- Register to view webcast here.
Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Summit
Steven Kelly , President and Chief Executive Officer, andMichael Klichinsky , PhD, Co-Founder and Chief Scientific Officer, will participate in a fireside chat.Monday, April 24, 2023 at11:00 am EDT - Virtual
- Register to view webcast here.
A replay of webcasts, when available, will be posted and archived at the Company's Investor Events webpage for a limited time following the event.
About Carisma Therapeutics
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to
Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in Exhibit 99.3 to Company's Current Report on Form 8-K filed with the
Media Contact:
(763) 350-5223
jstern@realchemistry.com
Investor Contact:
investors@carismatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-and-investor-conferences-in-april-2023-301792013.html
SOURCE